Icotrokinra

At a glance

---

What is icotrokinra?

Icotrokinra (research codes JNJ-77242113 and PN-235; brand name ICOTYDE) is a synthetic macrocyclic peptide -- a constrained, ring-shaped chain of amino acids -- engineered to do something biologics could not: block the interleukin-23 (IL-23) receptor as a once-daily pill.^[5] It was discovered by Protagonist Therapeutics using its peptide technology platform and co-developed with Johnson & Johnson, which markets the product worldwide.

That combination -- the precision of an IL-23 pathway drug with the convenience of an oral tablet -- is what makes icotrokinra notable. Psoriasis has been transformed over the past decade by injectable IL-23 inhibitors like guselkumab and risankizumab, which are highly effective. But they are injections, and injections are a real barrier for many people. Icotrokinra is the first drug to reach the same IL-23 target through the mouth rather than the needle.^[6]

In March 2026, the FDA approved icotrokinra for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy.^[6] Its approval was supported by a deep Phase 3 program (the four ICONIC trials) plus the earlier Phase 2b FRONTIER-1 study.^[1][2]

---

How it works

In plain terms, icotrokinra turns down an over-active immune signal that drives psoriasis. Psoriasis is fueled by a pathway called the IL-23/Th17 axis: the cytokine IL-23 activates immune cells that pump out inflammatory signals (IL-17A, IL-17F, IL-22), which make skin cells grow too fast and form the thick, scaly plaques of psoriasis. Icotrokinra blocks the very first step -- it sits on the IL-23 receptor and stops IL-23 from delivering its message.^[5]

What makes icotrokinra unusual is that it does this as an oral peptide. Most drugs that block a specific receptor this precisely are large antibody biologics that must be injected. Icotrokinra is a small, ring-shaped (macrocyclic) peptide designed to survive the gut well enough to act on the pathway.^[5]

Detailed mechanism (for advanced readers)

Icotrokinra is a selective IL-23 receptor antagonist peptide:^[5]

Target and potency:

• Binds the IL-23 receptor with picomolar affinity (KD 7.1 pM in human cells).
• Blocks IL-23-induced STAT3 phosphorylation with an IC50 of 5.6 pM.
• Does not affect IL-12 signaling (IL-12 and IL-23 share the p40 subunit, but icotrokinra is selective for the IL-23 receptor). This selectivity matters because IL-12 has distinct biological roles.

The IL-23/Th17 axis:

• IL-23 normally binds its receptor and triggers a JAK2/TYK2 → STAT3 signaling cascade inside Th17 and related immune cells.
• That cascade drives production of IL-17A, IL-17F, IL-22, and IFN-gamma -- the inflammatory cytokines central to plaque psoriasis.
• By antagonizing the receptor, icotrokinra suppresses this downstream cytokine output. This is the same biological node targeted by injectable IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) -- reached here with an oral peptide.

Oral peptide pharmacology:

• A chemically synthesized, constrained macrocyclic peptide (MW 1,898.19 g/mol). The ring structure improves stability and target engagement.
• Oral bioavailability is low (typical of peptides), but exposure is much higher in intestinal tissue, and systemic pharmacodynamic effects on the IL-23 pathway are observed despite modest plasma levels.
• Taken as one 200 mg tablet once daily, upon waking and 30 minutes before food.^[6]

How it differs from injectable IL-23 biologics: Antibody biologics (guselkumab, risankizumab) neutralize the IL-23 cytokine itself or its p19 subunit and are dosed by injection every 8-12 weeks. Icotrokinra instead blocks the receptor with a daily oral peptide. The target pathway is shared; the route, dosing rhythm, and molecule class are different.

---

What the research says

Icotrokinra cleared a high bar: a Phase 2b dose-finding study, four Phase 3 ICONIC trials including a head-to-head against another oral drug, efficacy in adolescents and in hard-to-treat areas, and an FDA approval. The evidence here is genuinely strong. The honest caveats are about the unknowns of any newly launched drug -- long-term, real-world safety -- and the absence of head-to-head data against the best injectable biologics.

Research timeline

Icotrokinra moved from a published oral-peptide proof of concept to an FDA approval in roughly two years:

Human clinical trials

Icotrokinra's approval rests on a Phase 2b dose-finding study (FRONTIER-1) plus the four-trial Phase 3 ICONIC program, spanning adults, adolescents, a head-to-head vs. another oral drug, and difficult-to-treat body sites:

Phase 2b (FRONTIER-1): Established that an oral peptide could meaningfully clear psoriasis and identified the dose carried into Phase 3.^[1]

Phase 3 ICONIC program: ICONIC-LEAD (placebo-controlled, ages 12+), ICONIC-ADVANCE 1 and 2 (placebo- and deucravacitinib-controlled), and ICONIC-TOTAL (high-impact scalp/genital disease).^[2][3][4]

---

What the evidence shows

Here is what the published research and the FDA label actually support about the most common questions:

---

Safety & side effects

What clinical trials show

Across the Phase 3 ICONIC program, icotrokinra's safety profile was favorable and close to placebo. Adverse-event rates were within about 1.1% of placebo through week 16, and no new safety signals emerged through week 52.^[6][2]

Most common adverse reactions:

• Headache
• Nausea
• Cough
• Fungal infection
• Fatigue
• Nasopharyngitis (common cold symptoms)

In ICONIC-LEAD, the overall rate of participants reporting at least one adverse event was essentially identical between icotrokinra and placebo through week 16 (about 49% in each group).^[2] In the head-to-head ICONIC-ADVANCE trials, icotrokinra had numerically lower adverse-event rates than the oral comparator deucravacitinib through 24 weeks.^[3]

What we don't know yet

Open questions about long-term safety

Icotrokinra is newly approved, so some questions can only be answered with time:

• Multi-year real-world safety: Trial data extend to roughly one year (week 52). Long-term, large-population safety patterns -- the kind captured by post-marketing surveillance -- are still accruing.
• Long-term infection risk: Short- and medium-term infection rates were close to placebo, but the long-run picture for any immunomodulator takes years of real-world data to characterize fully.
• Pregnancy and lactation: As with most newly approved systemic psoriasis drugs, human pregnancy data are limited; decisions should follow the label and provider counseling.
• Head-to-head vs. injectable biologics: Safety (and efficacy) relative to the best injectable IL-23 inhibitors has not been tested directly.

None of these are red flags -- they are the normal unknowns of a drug in its first year on the market. The controlled-trial safety record so far is reassuring.

---

Legal & regulatory status

As of June 2026:

FDA status

Icotrokinra is FDA-approved. On March 18, 2026, the FDA approved ICOTYDE (icotrokinra) for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy.^[6]

• It is a branded prescription drug. It is dispensed by pharmacies on a valid prescription -- like any other approved medication.
• It is not a compounded / 503A bulk peptide. Approved drugs that are commercially available are generally not eligible for routine compounding, and icotrokinra is a finished, branded tablet, not a bulk research substance.
• It is not a gray-market "research peptide." Any website or vendor offering "icotrokinra" outside the pharmacy system is not selling the FDA-approved product, and such products are unregulated and unverified.
• Dosing: One 200 mg tablet once daily, taken upon waking about 30 minutes before food.^[6]

WADA / anti-doping status

Icotrokinra is not specifically listed on the WADA Prohibited List. It is an immunology (IL-23 pathway) drug with no recognized performance-enhancing application and does not fall within the prohibited substance categories. Athletes should still confirm current status with their governing body, as lists are updated annually.

International status

Initial approval is in the United States (FDA, March 2026). Regulatory reviews in other regions are in progress. Johnson & Johnson markets the product; Protagonist Therapeutics discovered it.

---

How icotrokinra compares

Icotrokinra's natural comparators are the other systemic options for plaque psoriasis: the oral drug deucravacitinib (a TYK2 inhibitor, the one icotrokinra was tested against head-to-head) and the injectable IL-23 biologics like risankizumab and guselkumab. Only the deucravacitinib comparison is head-to-head; the biologic comparison relies on cross-trial data, which has important limitations.

The key tradeoffs:

• Head-to-head wins: Icotrokinra beat deucravacitinib -- the other leading oral systemic -- on skin clearance in two Phase 3 trials, with numerically lower adverse-event rates.^[3]
• Vs. injectable biologics: Cross-trial PASI 90 rates for the best injectable IL-23 inhibitors run somewhat higher than icotrokinra's ~50-57%. But there are no head-to-head trials against those biologics yet, and cross-trial comparisons are unreliable. The trial vs. ustekinumab (ICONIC-ASCEND) is ongoing.
• Route and convenience: Icotrokinra's defining advantage is being an effective IL-23-pathway drug you can take as a daily pill -- avoiding injections entirely. For people who avoid or struggle with injectable therapy, that can be the deciding factor.
• Track record: The injectable IL-23 biologics have years of real-world data across large populations. Icotrokinra, approved in 2026, has a strong trial record but is just beginning to accumulate real-world experience.

The bottom line: icotrokinra is a genuine advance -- the first oral peptide to hit the IL-23 receptor, with Phase 3 evidence and an FDA approval behind it. Its biggest selling point is the oral route. Whether it matches the very highest clearance rates of injectable biologics is not yet settled, because those head-to-head trials haven't been done.

---

Related content

Peptide

Linaclotide Profile

Another FDA-approved peptide medicine taken orally — a 14-amino-acid peptide for IBS-C and chronic constipation. A useful comparison for how approved peptide drugs differ from compounded research peptides.

Peptide

Elamipretide Profile

An FDA-approved mitochondria-targeted peptide. Like icotrokinra, it shows what 'approved prescription peptide' means versus the gray-market peptides often discussed online.

Guide

What Are Peptides?

A foundational primer — helpful context for understanding how a macrocyclic oral peptide like icotrokinra fits into the broader peptide landscape.

Guide

Peptide vs. Small Molecule vs. Biologic

Icotrokinra is an oral peptide that hits the same IL-23 target as injectable biologics. This guide explains why that distinction matters for access and convenience.

Tool

Peptide Tools

Interactive tools for understanding peptide dosing, half-life, and evidence — useful background for any approved peptide medicine.

---

References

1. [1]

   Bissonnette R, Pinter A, Ferris LK, et al.. “An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.” N Engl J Med. 2024. 390(6):510-521 DOI PubMedRCT

   FRONTIER-1 Phase 2b dose-ranging RCT (n=255). Established oral efficacy of the IL-23 receptor antagonist peptide and informed the 200 mg once-daily Phase 3 dose.

2. [2]

   Bissonnette R, Soung J, Hebert AA, et al.. “Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.” N Engl J Med. 2025. 393(18):1784-1795 DOI PubMedRCT

   ICONIC-LEAD pivotal Phase 3 RCT (NCT06095115; n=684, ages 12+). IGA 0/1 65% and PASI 90 50% at week 16 vs. 8% and 4% placebo. Basis for the approved indication.

3. [3]

   Stein Gold L, Armstrong AW, Bissonnette R, et al.. “Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.” Lancet. 2025. 406(10510):1363-1374 DOI PubMedRCT

   Two Phase 3 head-to-head RCTs vs. deucravacitinib. IGA 0/1 68-70% and PASI 90 55-57% at week 16. Superior to deucravacitinib on skin clearance with numerically lower adverse-event rates.

4. [4]

   Johnson & Johnson. “Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis (Phase 3 ICONIC-TOTAL, Week 16).” 2025. LinkRCT

   ICONIC-TOTAL Phase 3 (n=311). Overall IGA 0/1 57% vs. 6%; scalp IGA 0/1 66% vs. 11%; genital sPGA-G 0/1 77% vs. 21% at week 16. Full peer-reviewed publication pending at time of profiling.

5. [5]

   Fourie AM, Cheng X, Chang L, et al.. “JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans.” Sci Rep. 2024. 14(1):17515 DOI PubMedIn vitro

   Primary mechanism paper. Chemically synthesized macrocyclic peptide, MW 1,898.19 g/mol. IL-23R KD 7.1 pM; STAT3 IC50 5.6 pM; no effect on IL-12. Acts largely within intestinal tissue.

6. [6]

   Johnson & Johnson. “FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide.” 2026. LinkReview

   FDA approval announcement, March 18, 2026. Indication: moderate-to-severe plaque psoriasis in adults and adolescents 12+ weighing >=40 kg. One 200 mg tablet once daily. AE rates within 1.1% of placebo through week 16; no new safety signals through week 52.

7. [7]

   Protagonist Therapeutics. “Icotrokinra (JNJ-77242113 / PN-235): oral IL-23 receptor antagonist peptide discovered by Protagonist Therapeutics and developed with Johnson & Johnson.” 2026. LinkReview

   Background on discovery and collaboration. Discovered by Protagonist Therapeutics (PN-235) and co-developed/commercialized by Johnson & Johnson (JNJ-77242113).

8. [8]

   Sampogna F, Linder D, Romano GV, et al.. “Quality of life and psychosocial burden of psoriasis: sex differences in stigmatization and impact.” Dermatol Ther (Heidelb). 2021. DOIReview

   Representative of the literature showing women with psoriasis report a higher quality-of-life and stigmatization burden than men at comparable disease severity. Contextual, not interventional.

---